{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
oxcarbazepine
to a specific field?
There is one exact (name or code) match for oxcarbazepine
Status:
US Approved Rx
(2000)
Source:
NDA021014
(2000)
Source URL:
First approved in 2000
Source:
NDA021014
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Oxcarbazepine and its active metabolite (10,11-dihydro-10-hydroxy-carbazepine, MHD) have been effective in animal models of epilepsy that generally predict efficacy in generalized tonic-clonic seizures and partial seizures in humans. The pharmacokinetic profile of oxcarbazepine is less complicated than that of carbamazepine, with less metabolism by the cytochrome P450 system, no production of an epoxide metabolite, and lower plasma protein binding. The clinical efficacy and tolerability of oxcarbazepine have been demonstrated in trials in adults, children, and the elderly. The pharmacological activity of oxcarbazepine is primarily exerted through the 10-monohydroxy metabolite (MHD) of oxcarbazepine. The precise mechanism by which oxcarbazepine and MHD exert their antiseizure effect is unknown; however, in vitro electrophysiological studies indicate that they produce blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of
synaptic impulses. These actions are thought to be important in the prevention of seizure
spread in the intact brain. In addition, increased potassium conductance and modulation of high-voltage activated calcium channels may contribute to the anticonvulsant effects of the drug.
Status:
US Approved Rx
(2000)
Source:
NDA021014
(2000)
Source URL:
First approved in 2000
Source:
NDA021014
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Oxcarbazepine and its active metabolite (10,11-dihydro-10-hydroxy-carbazepine, MHD) have been effective in animal models of epilepsy that generally predict efficacy in generalized tonic-clonic seizures and partial seizures in humans. The pharmacokinetic profile of oxcarbazepine is less complicated than that of carbamazepine, with less metabolism by the cytochrome P450 system, no production of an epoxide metabolite, and lower plasma protein binding. The clinical efficacy and tolerability of oxcarbazepine have been demonstrated in trials in adults, children, and the elderly. The pharmacological activity of oxcarbazepine is primarily exerted through the 10-monohydroxy metabolite (MHD) of oxcarbazepine. The precise mechanism by which oxcarbazepine and MHD exert their antiseizure effect is unknown; however, in vitro electrophysiological studies indicate that they produce blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of
synaptic impulses. These actions are thought to be important in the prevention of seizure
spread in the intact brain. In addition, increased potassium conductance and modulation of high-voltage activated calcium channels may contribute to the anticonvulsant effects of the drug.
Status:
US Approved Rx
(2023)
Source:
ANDA211236
(2023)
Source URL:
First approved in 2013
Source:
NDA022416
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Eslicarbazepine acetate is a third generation antiepileptic drug indicated for the treatment of partial-onset seizures. Structurally, it belongs to the dibenzazepine family and is closely related to carbamazepine and oxcarbazepine. Eslicarbazepine acetate was developed by scientists in Portugal. Its main mechanism of action is by blocking the voltage-gated sodium channel. Eslicarbazepine acetate is a pro-drug that is rapidly metabolized almost exclusively into eslicarbazepine (S-licarbazepine), the biologically active drug. It has a favorable pharmacokinetic and drug-drug interaction profile. However, it may induce the metabolism of oral contraceptives and should be used with caution in females of child-bearing age.
Status:
US Approved Rx
(2000)
Source:
NDA021014
(2000)
Source URL:
First approved in 2000
Source:
NDA021014
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Oxcarbazepine and its active metabolite (10,11-dihydro-10-hydroxy-carbazepine, MHD) have been effective in animal models of epilepsy that generally predict efficacy in generalized tonic-clonic seizures and partial seizures in humans. The pharmacokinetic profile of oxcarbazepine is less complicated than that of carbamazepine, with less metabolism by the cytochrome P450 system, no production of an epoxide metabolite, and lower plasma protein binding. The clinical efficacy and tolerability of oxcarbazepine have been demonstrated in trials in adults, children, and the elderly. The pharmacological activity of oxcarbazepine is primarily exerted through the 10-monohydroxy metabolite (MHD) of oxcarbazepine. The precise mechanism by which oxcarbazepine and MHD exert their antiseizure effect is unknown; however, in vitro electrophysiological studies indicate that they produce blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of
synaptic impulses. These actions are thought to be important in the prevention of seizure
spread in the intact brain. In addition, increased potassium conductance and modulation of high-voltage activated calcium channels may contribute to the anticonvulsant effects of the drug.
Status:
Investigational
Source:
NCT02281591: Phase 1 Interventional Completed Epilepsy
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Licarbazepine, (R)- is a hydroxy derivative of R-licarbazepine acetate. Eslicarbazepine acetate (ESL), or S-licarbazepine acetate (ESL), Licarbazepine, (R)- acetate and their racemic mixture, as well as other related compounds, were orally assessed in rats for anticonvulsant activity and compared with carbamazepine (CBZ) and oxcarbazepine (OXC). Metabolism of OXC and its derivatives varies considerably between species. Rats metabolize ESL to OXC with minimal (S)-licarbazepine or Licarbazepine, (R)- metabolites. Licarbazepine, (R)- undergoes a further oxidation to the trans-diol metabolite, demonstrating an increased predisposition to earlier inactivation. Administration of ESL and of eslicarbazepine significantly protected mice against Maximal electroshocks-induced seizures, whereas that of Licarbazepine, (R)- failed to provide protection. This finding raises doubts on the contribution of Licarbazepine, (R)- as an active anticonvulsant.
